Arthritis and Musculoskeletal Alliance
Influencing policy and care together for best lifelong musculoskeletal health
Researchers from the University of the Highlands and Islands invite people to take a survey as part of a research study about how people living with chronic MSK to share their views on massage therapy as a form of pain management.
The survey is open until 31st January 2026.
You can access the survey here.
In two new NRAS videos, our Scottish Ambassadors and Dr Neil McKay from the Scottish Society for Rheumatology, explain how RA patients living in Scotland can help shape improvements to their rheumatology services.
Patients who have had RA for a year or more, and live in Scotland, can fill out the questionnaires that will be available in your clinic. Information gathered will be analysed and used to identify areas of good practice that can be shared across the country.
On Monday 8th May 2017 the Scottish Medicines Consortium (SMC) published new advice accepting the restricted use of belimumab (Benlysta) by NHS Scotland for lupus patients. This advice was published following a re-submission with evidence supplied by GlaxoSmithKline (the producers of Benlysta) and LUPUS UK on behalf of patients.
Belimumab is the first drug approved to treat lupus in more than 50 years and is the first drug developed specifically for lupus since the disease was discovered. It is approved for adults with active, systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.…
Read more of this article
In the past month LUPUS UK has published updated versions of three of our information leaflets/booklets. These publications were updated to ensure that they meet the requirements of the Information Standard and reflected the most up-to-date evidence.
Physical copies are available to order free of charge from LUPUS UK National Office, or you can read/download them on our website by following the hyperlinks:
Contribution to the Scottish Medicines Consortium’s (SMC) consultation of the use of Benlysta (belimumab) in SLE
Benlysta (belimumab) is due to be discussed by the SMC and a decision made for its use by certain SLE patients in Scotland.…
Read more of this article
| Disease | Risk Reduction via Regular Physical Activity |
| Heart Disease | 40% |
| Stroke | 27% |
| Colon Cancer | 25% |
| Breast Cancer | 24% |
| Type 2 Diabetes | 30% |
| Hypertension | 50% |
| Source: A Fresh Approach in Practice – NHS North West and the FSEM UK 2011 | |
The Faculty of Sport and Exercise Medicine (FSEM) UK has responded to the Scottish Parliament Health and Sport Committee Preventative Agenda Inquiry, emphasising the risk reduction for many common conditions and the cost savings which can be made by greater use of Sport and Exercise Medicine (SEM) services in the NHS.…
Read more of this article
